AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

Calendar

09-30 Earnings release - Q2 2026

More about the company

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets 12:57:29 2026-05-28 EDT			5-day change	1st Jan Change
1.120 ^USD	-90.26%		-.--%	-22.76%

08-17	AB Science completes settlement and delivery of its private placement
08-10	AB Science Wraps Up EUR14 Million Private Placements	MT

Market Cap	55.45M 64.75M 51.86M 47.45M 89.31M 6.2B 90.32M 613M 239M 3.11B 243M 238M 10.29B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	55.45M 64.75M 51.86M 47.45M 89.31M 6.2B 90.32M 613M 239M 3.11B 243M 238M 10.29B	EV / Sales 2026 *	46.2x	EV / Sales 2027 *	42.7x
Free-Float	69.03%	Yield 2026 *	-	Yield 2027 *	-

08-17	AB Science completes settlement and delivery of its private placement
08-10	AB Science Wraps Up EUR14 Million Private Placements	MT
08-10	AB Science raises €14.2m
07-13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
07-10	AB Science streamlines its portfolio and refocuses on two molecules
07-10	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
07-08	Stéphane Ledermann takes the helm at AB Science as CEO
07-06	AB Science S.A. Announces Board Changes	CI
07-06	AB Science S.A. Announces CEO Changes	CI
07-02	AB Science S.A. announced that it has received $2.01616 million in funding	CI
07-01	AB Science, successful private placement
06-30	AB Science S.A. announced that it has received ?2.294 million in funding	CI
06-29	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI

08-17	AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026	GL
08-10	AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million	GL
08-04	AB Science : Webconference presentation on masitinib + isoquercetin in COVID-19	PU
07-10	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
07-08	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU

AB Science Stock OTC Markets

Stocks

ABSCF

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quarterly revenue - Rate of surprise

08-17	Bourse : Stellantis s'agite, ArgenX communique et PayPal fait monter les enchères
08-17	AB Science procède au règlement-livraison de son placement privé
08-17	AB Science : annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026
08-17	AB Science annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026
08-10	Au terme d'une séance calme, l'Europe en ordre dispersé

Current year	1.12	1.37
1 year	1.12	1.45
3 years	0	3.84
5 years	0	17.1
10 years	0	26.7

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	2026-07-06
Laurent Guy DFI	Director of Finance/CFO	-	2009-11-19
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	2018-03-31

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	2001-07-10
Patrick Moussy BRD	Director/Board Member	-	2011-09-19
Cécile de Guillebon BRD	Director/Board Member	64	2021-06-26

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-90.26%	-.--%	-	-	64.73M
MERCK & CO., INC.	+2.39%	+12.30%	+74.60%	+42.26%	376B
MERCK KGAA	-0.07%	+1.21%	+23.00%	-12.63%	70.02B
HALOZYME THERAPEUTICS, INC.	+1.93%	+9.64%	+50.61%	+153.33%	12.28B
KYOWA KIRIN CO., LTD.	-1.85%	-0.12%	-2.37%	-1.49%	8.49B
SK BIOPHARMACEUTICALS CO., LTD.	-3.24%	-4.12%	-15.37%	-2.90%	4.73B
YUHAN CORPORATION	-1.32%	-1.67%	-28.43%	+17.57%	4.43B
BETTA PHARMACEUTICALS CO., LTD.	-8.11%	-25.49%	-21.31%	+13.56%	3.2B
SUPERNUS PHARMACEUTICALS, INC.	-3.37%	-5.01%	+2.16%	+43.64%	2.67B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-2.76%	-3.99%	-13.95%	-6.87%	2.11B
Average	-10.67%	-1.99%	+7.66%	+27.38%	53.81B
Weighted average by Cap.	+1.72%	+9.70%	+61.95%	+35.31%

	2026 *	2027 *
Net sales	1.2M 1.4M 1.12M 1.03M 1.93M 134M 1.95M 13.27M 5.17M 67.34M 5.26M 5.15M 223M	1.3M 1.52M 1.22M 1.11M 2.09M 145M 2.12M 14.38M 5.6M 72.95M 5.7M 5.57M 241M
Net income	-	-
Net Debt	-	-